Successful Tezepelumab Response and the Usefulness of Serum TARC Level as a Biomarker in a Severe Type 2 Bronchial Asthma Patient After Dupilumab, Mepolizumab, and Benralizumab Failure

Fumihiro Kashizaki; Yu Matsumoto; Michiko Hirokado; Naomi Kawano; Ryo Ikoma

doi:10.69854/jcq.2024.0009

Journal of Clinical Question

ISSN 2759-534X

LOADING ARTICLE...

Successful Tezepelumab Response and the Usefulness of Serum TARC Level as a Biomarker in a Severe Type 2 Bronchial Asthma Patient After Dupilumab, Mepolizumab, and Benralizumab Failure - Journal of Clinical Question